UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 27, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

AnaptysBio, Inc.

File No. 333-206849 - CF#32802

AnaptysBio, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 filed on September 9, 2015, as amended.

Based on representations by AnaptysBio, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.9	through August 6, 2025
Exhibit 10.10	through May 2, 2024
Exhibit 10.11	through August 6, 2025
Exhibit 10.12	through May 18, 2025

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary